Strategic partnership Disarm Therapeutics pursued a high-value exit via acquisition by Lilly for up to 1.6B total, signaling strong market validation and potential for collaboration on large-scale translational programs or co-development opportunities with pharma partners.

Neurology focus The company targets axonal degeneration across multiple CNS, ocular, and peripheral nervous system diseases, presenting multiple entry points for companion diagnostics, biomarker development collaborations, and modality extensions with pharma seeking disease-modifying therapies.

Early stage, high interest With recent preclinical milestones and a leadership pedigree, Disarm sits at an attractive stage for early collaboration deals, licensing opportunities, or value-adding partnerships to accelerate development of SARM1 inhibitors.

Financing signals Revenue of 1–10M and historical funding activity, plus past large-licensing potential, indicate capacity for milestone-driven deals and co-funding collaborations to advance late-preclinical to clinical programs.

Strategic fit opportunities Key disease areas include multiple sclerosis, ALS, glaucoma, and peripheral neuropathies; potential buyers or partners across neurology, ophthalmology, and CNS pharma could leverage Disarm’s SARM1 inhibitor platform for combination therapies or disease-modifying strategies.